<1α(Z),2β,5α>-(+/-)-7-<5<<(1,1'-biphenyl)-4-yl>methoxy>-2-(4-morpholinyl)-3-oxocyclopentyl>-4-heptenoic acid | 81443-73-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: <1α(Z),2β,5α>-(+/-)-7-<5<<(1,1'-biphenyl)-4-yl>methoxy>-2-(4-morpholinyl)-3-oxocyclopentyl>-4-heptenoic acid
• 英文别名: [1α(Z),2β,5α]-(+/-)-7-[5-[[(1,1'-biphenyl)-4-yl]methoxy]-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid；AH23848B；AH23848；[1α(Z), 2β, 5α]-(+/-)-7-[5-[[(1,1'-biphenyl)-4-yl]methoxy]-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid；(1α(Z),2β,5α)-(+/-)-7-(5{[(1,1'-biphenyl)-4-yl]methoxy}-2-(4-morpholinyl)-3-oxocyclopentyl)-4-heptenoic acid；(4Z)-7-[(1S,2S,5R)-5-[([1,1'-biphenyl]-4-yl)methoxy]-2-(morpholin-4-yl)-3-oxocyclopentyl]hept-4-enoic acid；(Z)-7-[(1S,2S,5R)-2-morpholin-4-yl-3-oxo-5-[(4-phenylphenyl)methoxy]cyclopentyl]hept-4-enoic acid
• CAS: 81443-73-4
• 化学式: C₂₉H₃₅NO₅
• 分子量: 477.601
• InChiKey: IOFUFYLETVNNRF-FKQKSGFWSA-N

物化性质

• 溶解度：
  在DMSO中的溶解度为18 mg/mLat ≤60 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Method to enhance tissue regeneration
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US10736906B2

  公开（公告）日：2020-08-11

  The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.

  本发明提供了使用组织生长调节剂调节组织生长的组合物和方法，组织生长调节剂是通过调节 PG 或 Wnt 信号通路，或同时使用 PG 和 Wnt 信号通路的调节剂以产生协同效应或高度选择性效应，从而根据特定适应症的需要增强或抑制组织生长的制剂。
• METHOD TO ENHANCE TISSUE REGENERATION
  申请人：Children's Medical Center Corporation

  公开号：EP2077826B1

  公开（公告）日：2013-09-04
• INHIBITION OF PROSTGLANDIN E2 RECEPTORS FOR THE TREATMENT OF ENDOMETRIOSIS
  申请人：Arosh Joe A.

  公开号：US20100249125A1

  公开（公告）日：2010-09-30

  The present invention describes the selective inhibition of prostaglandin receptors (PGE 2 ), e.g., EP2 and EP4, by one or more inhibitors are selected from 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid and (4Z)-7-[(rel-1S,2S,5R)-5-((1,1′-Biphenyl-4-yl)methoxy)-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid and salts thereof as a potential therapeutic tool or to expand the spectrum of currently available treatment options for endometriosis and other chronic gynecological diseases in reproductive age women. PGE 2 inhibition through novel cell signaling mechanisms identified by the present invention provides an effective and attractive therapeutic tool for treatment without compromising pregnancy and sex life in the women.
• US9402852B2
  申请人：——

  公开号：US9402852B2

  公开（公告）日：2016-08-02